FDA sched­ules March ODAC for Geron's MDS drug fol­low­ing PhI­II da­ta

Bay Area biotech Geron’s stock dipped slight­ly Mon­day af­ter the FDA an­nounced an On­co­log­ic Drugs Ad­vi­so­ry Com­mit­tee for the com­pa­ny’s ex­per­i­men­tal drug ime­tel­stat.

Ime­tel­stat is an in­jectable drug de­signed to treat adult pa­tients with ane­mia who are de­pen­dent on trans­fu­sions, and who al­so have myelodys­plas­tic syn­dromes (MDS). The com­pa­ny has ap­plied for ap­proval in pa­tients who have failed to re­spond, or have lost re­sponse to, or are in­el­i­gi­ble for ery­thro­poiesis-stim­u­lat­ing treat­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER